mardi 19 décembre 2017

Onco Actu du 19 décembre 2017


1. Biologie

Study prompts new ideas on cancers’ origins [WUSTL]

3. Prévention

Where does cancer come from? We must talk about preventable risk [The Guardian]

3.3 Prévention - Vaccins

What the Gardasil Testing May Have Missed [Slate]

Et Tu, Slate? Flaws with Their Questions About Gardasil [vaxopedia]

4.1 Dép., diag. & prono. - Prostate

Could Genomics Influence Prostate Cancer Treatment? [Cancer Research Catalyst]

4.2 Dép., diag. & prono. - Génome

Genetic Variation Gets More Real All the Time [In the Pipeline]

4.9 Dép., diag. & prono. - Sein

Mutational Signatures May Identify Patients with Breast Cancer Most Likely to Benefit from Platinum-based Chemotherapy [AACR]

5.12 Immunothérapies

Keytruda falls hard at gastric cancer hurdle [Pharmafile]

5.12.1 Immunothérapies - partenariats

Regeneron pairs PD-1 latecomer with ISA’s HPV immunotherapy [FierceBiotech]

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo [EndPoints]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma [BMS]

5.2 Pharma

Roche touts Swiss-led R&D unit after years in Genentech's shadow [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

Brentuximab Vedotin Approved for Two Rare Lymphomas [NCI]

5.7 SABCS

A New PARP Drug For Breast Cancer? I'm Thrilled! [Forbes]

6.1 Observation

Cancer survivors age faster and die sooner, major study suggests [The Telegraph]

Cervical cancer deaths in over-50s predicted to rise sharply in England [The Guardian]

6.5 Médecines alternatives

FDA proposes new, risk-based enforcement priorities to protect consumers from potentially harmful, unproven homeopathic drugs [FDA]

FDA officials to target high-risk alternative remedies [STAT]

6.7 DMP, Big Data & applis

Could Bitcoin technology help science? [Nature]

6.9 Controverses

Ms. Inappropriate Defends The Status Quo [CardioBrief]